243 related articles for article (PubMed ID: 29673807)
1. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
Tallarico M; Foster JC; Seisler D; Lafky JM; Hurria A; Jatoi A; Cohen HJ; Muss HB; Bartlett N; Cheson BD; Jung SH; Leonard JP; Byrd JC; Nabhan C
J Geriatr Oncol; 2018 Jul; 9(4):321-328. PubMed ID: 29673807
[TBL] [Abstract][Full Text] [Related]
2. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
3. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
[TBL] [Abstract][Full Text] [Related]
4. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
5. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
6. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
[TBL] [Abstract][Full Text] [Related]
7. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
[TBL] [Abstract][Full Text] [Related]
8. Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.
Chang TW; Weaver AL; Shanafelt TD; Habermann TM; Wriston CC; Cerhan JR; Call TG; Brewer JD
Int J Dermatol; 2017 Nov; 56(11):1125-1129. PubMed ID: 28685851
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
13. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution.
Roncadin M; Arcicasa M; Zagonel V; Bortolus R; Valeri P; Pinto A; De Paoli A; Franchin G; Carbone A; Trovò MG
Cancer; 1994 Aug; 74(3):978-84. PubMed ID: 8039128
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
15. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Famenini S; Martires KJ; Zhou H; Xavier MF; Wu JJ
J Am Acad Dermatol; 2015 Jan; 72(1):78-84. PubMed ID: 25440434
[TBL] [Abstract][Full Text] [Related]
16. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
18. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
19. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]